A gene drug delivery system for enhancing the effect of photothermal therapy of tumors

By modifying the Au-GPLGLAG-CS/HSP 70 siRNA system that binds gold nanorods to chitosan using MMP-2-sensitive peptides at the tumor site, the deep delivery of siRNA is achieved, solving the increase in heat shock proteins in photothermal therapy. The tolerance problem has significantly improved the effect of tumor treatment.

CN117338927BActive Publication Date: 2024-11-05CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311352202.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-19
Publication Date
2024-11-05
Estimated Expiration
2043-10-19

AI Technical Summary

Technical Problem

Traditional tumor treatment methods such as photothermal therapy have increased cell tolerance due to the increase of heat shock proteins, which weakens the therapeutic effect, and siRNA is difficult to pass through the cell membrane and resist degradation, limiting the effectiveness of gene therapy.

Method used

An Au-GPLGLAG-CS/HSP 70 siRNA gene delivery system was designed, using MMP-2-sensitive peptide to modify the gold nanorods to bind to chitosan, achieving deep targeted delivery of siRNA, and inhibiting heat shock proteins through RNA interference technology. Expression of 70 improves the efficacy of photothermal therapy.

Benefits of technology

Deep-level gene drug delivery of tumors is achieved, the expression of heat shock protein 70 is reduced, the effect of photothermal treatment is enhanced, and the targeted and therapeutic effect of tumor treatment is significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117338927B_ABST
    Figure CN117338927B_ABST
Patent Text Reader

Abstract

The present invention discloses a gene drug delivery system for enhancing the photothermal therapy effect of tumors, Au-GPLGLAG-CS / HSP 70 siRNA (AGC / siRNA), which has MMP-2 sensitive response, can be used for deep-level HSP 70 siRNA gene delivery in tumors, and can reverse tumor photothermal tolerance. The present invention further discloses the cellular uptake of the delivery system, the penetration of tumor spheres, the safety and in vitro anti-cell proliferation ability, the effect of silencing the HSP 70 gene, the effect of downregulating the expression of HSP 70, the efficiency of promoting cell apoptosis, and further discloses the effect of inhibiting tumor growth in mice bearing triple-negative breast cancer 4T1 tumors and the tumor penetration and retention effect of the delivery system.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention discloses a multifunctional nano drug delivery system Au-GPLGLAG-CS / HSP 70siRNA (AGC / siRNA) with MMP-2 sensitive response, used for deep tumor HSP 70siRNA gene delivery, capable of reversing tumor photothermal tolerance, discloses a preparation method of a multifunctional nano drug delivery system with MMP-2 enzyme sensitive response in tumor microenvironment, discloses its nanostructure, discloses the cell uptake of the delivery system, discloses its penetration of tumor spheres, discloses its carrier safety and in vitro anti-cell proliferation ability, discloses its effect of silencing HSP 70 gene, discloses its effect of downregulating HSP 70 expression, discloses its efficiency of promoting cell apoptosis, and further discloses its effect of inhibiting tumor growth in mouse triple-negative breast cancer 4T1 tumor-bearing mice and the tumor penetration and retention effect of the delivery system. Therefore, the application of the multifunctional nano drug delivery system in reversing tumor photothermal tolerance and enhancing gene drug delivery efficiency is clarified. It belongs to the field of biomedicine. Background Art

[0002] Cancer is now the first or second most common cause of premature death in most countries of the world. The number of new cancer cases worldwide is expected to increase by approximately 50% over the next 20 years. Cancer is becoming a global health challenge that knows no borders.

[0003] Traditional tumor treatments include surgery, chemotherapy, and radiotherapy, which have high risks, severe side effects, and are prone to recurrence and metastasis. Therefore, countries are committed to developing a new type of cancer treatment method that is safe, effective, and has few toxic side effects. Photothermal therapy in ablation therapy has developed rapidly because of its less invasiveness, high selectivity, repeatable treatment, and few side effects.

[0004] Photothermal therapy also has inherent defects. First, a high temperature of more than 50°C is required to effectively remove the tumor, but due to heat diffusion, healthy tissues near the cancer cells may be damaged; at the same time, rapid heating can induce an immune response, causing a rapid increase in heat shock protein (Heat shock protein, Hsp), increasing the cell's tolerance to heat, and thus weakening the therapeutic effect of photothermal therapy. To fundamentally solve the problem, it is necessary to inhibit the expression of heat shock protein and regulate the cell metabolic process to form low-temperature photothermal therapy (Low-temperature PTT, LTPTT). The present invention uses small interfering RNA technology in gene therapy to specifically inhibit the generation of heat shock protein at the gene level, thereby improving the efficacy of low-temperature photothermal therapy.

[0005] However, since siRNA itself contains free nucleic acids and phosphate groups, it is a densely negatively charged molecule; at the same time, its molecular weight is relatively large. The above two points prevent it from passing through the cell membrane by passive diffusion like small molecules and ions. In addition, siRNA is easily destroyed and degraded by the acidic environment in the endosome-lysosome system and the ribozymes present in the blood, and the effect of RNA interference is limited. The present invention selects the only polycationic alkaline polysaccharide in nature, the non-viral vector chitosan, as the gene carrier of siRNA. Chitosan can interact with nucleic acids to form nanoparticles with uniform particle size, and at the same time, it plays a good protective role for nucleic acids and promotes gene delivery.

[0006] In order to achieve deep tumor siRNA delivery, the present invention uses matrix metalloproteinase-2 (MMP-2) sensitive polypeptide to modify and connect gold nanorods and gene-carrying chitosan, so that it actively targets tumor tissues, releases siRNA at the tumor site, promotes deep drug delivery of siRNA in the form of chitosan-siRNA complex, efficiently inhibits the expression of heat shock protein 70, and improves the efficacy of photothermal therapy induced by gold nanorods. The multifunctional nano drug delivery system designed by the present invention can achieve deep tumor gene drug delivery, improve gene therapy effects, and solve the tolerance of photothermal therapy caused by increased heat shock proteins through photothermal combined with gene therapy, greatly improving the effect of photothermal therapy, and providing new ideas and solutions for tumor treatment.

[0007] The present invention first synthesizes gold nanorods with uniform particle size and rod-shaped structure by seed growth method, modifies MMP-2 enzyme sensitive polypeptide on its surface by Au-S bond, and finally connects chitosan to the carboxyl end of polypeptide by amide bond, and successfully prepares AGC gene delivery vector. The present invention utilizes the synergistic treatment strategy of RNA interference technology to improve the photothermal treatment effect of gold nanorods on tumors, and confirms the therapeutic effect of the delivery system by various evaluation studies. Based on this discovery, the inventor proposed the present invention. Summary of the invention

[0008] One object of the present invention is to invent a gene drug delivery system for enhancing the effect of photothermal therapy of tumors, whose structure is Au-GPLGLAG-CS / HSP 70siRNA, sometimes referred to as AGC / siRNA in the present invention; wherein, the Au-GPLGLAG-CS is a gene delivery vector specific to MMP-2 in the tumor microenvironment, sometimes referred to as AGC in the present invention; HSP70siRNA is a gene drug that downregulates the expression of HSP 70, sometimes referred to as siRNA in the present invention.

[0009] The gene drug delivery system of the present invention is preferably prepared by co-incubating Au-GPLGLAG-CS and HSP 70 siRNA at a mass ratio of 27.58:1.

[0010] The gene drug delivery system of the present invention is a rod-shaped nanostructure.

[0011] The present invention further provides a method for preparing the gene drug delivery system, which comprises the following steps: co-incubating Au-GPLGLAG-CS and HSP 70 siRNA with shaking on a shaker at room temperature overnight, and centrifuging to obtain the gene drug delivery system.

[0012] Preferably, the preparation method described in the present invention comprises the following steps: dissolving 1OD HSP 70 siRNA (33 μg) in 250 μL DEPC water to prepare a 10 μmol / L HSP 70 siRNA solution; mixing 1 μL HSP 70 siRNA and 100 μL Au-GPLGLAG-CS, and incubating them overnight at room temperature on a shaker.

[0013] The preparation method of the present invention, wherein the preparation method of Au-GPLGLAG-CS is: AuNRs and Mpa-GPLGLAG-COOH react to obtain Au-GPLGLAG-COOH, and then CS is connected to the polypeptide through an amide bond.

[0014] Preferably, the preparation method of Au-GPLGLAG-CS is as follows:

[0015] 1) Preparation of gold nanoparticle seed solution

[0016] Prepare 3 mL of 0.1 M CTAB solution with deionized water, add 0.1 mL of 0.01 M chloroauric acid to it at room temperature and mix well; add 0.24 mL of 0.01 M ice-cold sodium borohydride under vigorous stirring (1500 rpm), and activate in a water bath at 28°C in the dark for 60 min;

[0017] 2) Preparation of growth solution

[0018] Prepare 40 mL of 0.1 M CTAB solution with deionized water, add 2 mL of 0.01 M chloroauric acid to it at room temperature and mix well; add 400 μL of 0.01 M silver nitrate solution, 400 μL of 0.1 M ascorbic acid solution and 1.6 mL of 1 M dilute hydrochloric acid in sequence and mix well; finally add 100 μL of seed solution; seal with sealing film, wrap with tin foil, and stand in a 28°C water bath in the dark overnight;

[0019] 3) Concentration of gold nanorod solution

[0020] 800 μL of the growth solution was pipetted into a 2 mL centrifuge tube, centrifuged at 9000 rpm for 12 min, 600 μL of the supernatant was carefully discarded with a pipette, and the solution was resuspended to obtain a concentrated solution of gold nanorods;

[0021] 4) Preparation of AuNRs-GPLGLAG-COOH

[0022] Weigh 6 mg of Mpa-GPLGLAG-COOH polypeptide and dissolve it thoroughly with 1 mL of deionized water by ultrasonication. Add 200 μL of concentrated gold nanorod solution dropwise under magnetic stirring in a 25°C water bath and react for 24 h in the dark. After the reaction is terminated, centrifuge and discard the supernatant. The resulting precipitate contains AuNRs-GPLGLAG-COOH.

[0023] 5) Preparation of AuNRs-GPLGLAG-CS

[0024] Weigh 4 mg of chitosan (CS) and dissolve it in 1 mL of 0.1 M MES solution, and sonicate for 30 min; centrifuge the AuNRs-GPLGLAG-COOH aqueous solution at 9000 rpm for 10 min, and remove the supernatant; then add the sonicated chitosan MES solution to the AuNRs-GPLGLAG-COOH precipitate, and continue sonicating for 1 h; weigh 3 mg of EDC and NHS respectively, and dissolve them in 0.2 mL of MES solution respectively; after 1 h, first slowly add 0.2 mL of NHS solution into the system, then slowly add 0.2 mL of EDC solution, and finally add 0.1 mL MES solution to make the total solution system 1.5mL; continue ultrasonication for 3h, then transfer it to a magnetic stirrer and stir it in the dark at 25℃ for 19h; after the reaction stops, centrifuge at 9000rpm for 10min and discard the supernatant; wash it twice with 1% acetic acid solution and once with pure water to convert its system to neutral; finally, resuspend it with deionized water to obtain the AuNRs-GPLGLAG-CS carrier.

[0025] The present invention further provides the use of the gene drug delivery system in preparing a nanocarrier system for reversing photothermal tolerance and enhancing tumor cell killing.

[0026] Another object of the present invention is to provide an application of a gene delivery system in the preparation of a drug for inhibiting tumors.

[0027] Another object of the present invention is to evaluate the efficiency of the gene delivery system AGC / siRNA in down-regulating HSP 70 expression at the mRNA and protein levels.

[0028] Another object of the present invention is to evaluate the effect of the gene delivery system AGC / siRNA in inhibiting tumor cell proliferation.

[0029] Another object of the present invention is to evaluate the efficiency of the gene delivery system AGC / siRNA in promoting cell apoptosis.

[0030] Another objective of the present invention is to evaluate the effect of the gene delivery system AGC / siRNA on the penetration of tumor spheres.

[0031] Another object of the present invention is to evaluate the effect of the gene delivery system AGC / siRNA in inhibiting tumor growth in mice bearing triple-negative breast cancer 4T1.

[0032] Another object of the present invention is to prepare the gene drug delivery system of the present invention into a usable pharmaceutical preparation, wherein the pharmaceutical preparation is preferably in the form of an injection.

[0033] To this end, the present invention provides an injection, and its preparation method is as follows:

[0034] 1) Preparation of gold nanoparticle seed solution

[0035] Prepare 3 mL of 0.1 M CTAB solution with deionized water, add 0.1 mL of 0.01 M chloroauric acid to it at room temperature and mix well; add 0.24 mL of 0.01 M ice-cold sodium borohydride under vigorous stirring (1500 rpm), and activate in a water bath at 28°C in the dark for 60 min;

[0036] 2) Preparation of growth solution

[0037] Prepare 40 mL of 0.1 M CTAB solution with deionized water, add 2 mL of 0.01 M chloroauric acid to it at room temperature and mix well; add 400 μL of 0.01 M silver nitrate solution, 400 μL of 0.1 M ascorbic acid solution and 1.6 mL of 1 M dilute hydrochloric acid in sequence and mix well; finally add 100 μL of seed solution; seal with sealing film, wrap with tin foil, and stand in a 28°C water bath in the dark overnight;

[0038] 3) Concentration of gold nanorod solution

[0039] 800 μL of the growth solution was pipetted into a 2 mL centrifuge tube, centrifuged at 9000 rpm for 12 min, 600 μL of the supernatant was carefully discarded with a pipette, and the solution was resuspended to obtain a concentrated solution of gold nanorods;

[0040] 4) Preparation of AuNRs-GPLGLAG-COOH

[0041] Weigh 6 mg of Mpa-GPLGLAG-COOH polypeptide and dissolve it thoroughly with 1 mL of deionized water by ultrasonication. Add 200 μL of concentrated gold nanorod solution dropwise under magnetic stirring in a 25°C water bath and react for 24 h in the dark. After the reaction is terminated, centrifuge and discard the supernatant. The resulting precipitate contains AuNRs-GPLGLAG-COOH.

[0042] 5) Preparation of AuNRs-GPLGLAG-CS

[0043] Weigh 4 mg of chitosan (CS) and dissolve it in 1 mL of 0.1 M MES solution, and sonicate for 30 min; centrifuge the AuNRs-GPLGLAG-COOH aqueous solution at 9000 rpm for 10 min, and remove the supernatant; then add the sonicated chitosan MES solution to the AuNRs-GPLGLAG-COOH precipitate, and continue sonicating for 1 h; weigh 3 mg of EDC and NHS respectively, and dissolve them in 0.2 mL of MES solution respectively; after 1 h, first slowly add 0.2 mL of NHS solution into the system, then slowly add 0.2 mL of EDC solution, and finally add 0.1 mL MES solution to make the total solution system 1.5mL; continue ultrasonication for 3h, then transfer it to a magnetic stirrer and stir it in the dark at 25℃ for 19h; after the reaction stops, centrifuge at 9000rpm for 10min and discard the supernatant; wash it twice with 1% acetic acid solution and once with pure water to convert its system to neutral; finally, resuspend it with deionized water to obtain the AuNRs-GPLGLAG-CS carrier.

[0044] 6) Preparation of AGC / HSP 70 siRNA

[0045] 1OD HSP 70 siRNA (33 μg) was dissolved in 250 μL DEPC water to prepare a 10 μmol / L HSP 70 siRNA solution; 1 μL HSP 70 siRNA and 100 μL Au-GPLGLAG-CS were mixed, incubated overnight at room temperature on a shaker, and the loaded and unloaded genes were separated by centrifugation, and resuspended in a PBS solution.

[0046] When used, it is added into a pharmaceutically acceptable carrier to prepare an injectable pharmaceutical preparation.

[0047] Further explanation of the following words appearing in the manual:

[0048] AuNRs: gold nanorods

[0049] CS: chitosan

[0050] HSP 70:Heat shock protein 70, heat shock protein 70

[0051] MMP-2: Matrix metalloproteinase, matrix metalloproteinase-2

[0052] Au metal atoms

[0053] GPLGLAG is a peptide sequence that specifically recognizes matrix metalloproteinase-2 in the tumor microenvironment (a peptide with a known structure, see the literature ACPI Conjugated Gold Nanorods as Nanoplatform for Dual Image GuidedActivatable Photodynamic and Photothermal Combined Therapy In Vivo)

[0054] Its chemical structure is as follows:

[0055]

[0056] Its sources are as follows: synthesized by Nanjing Peptide Company

[0057] Mpa-GPLGLAG-COOH mercaptopropionic acid modified MMP-2 sensitive sequence peptide HSP 70 siRNA Mouse heat shock protein 70 small interfering RNA (small interfering RNA with known structure, see the literature small interfering RNA down-regulation of heat shock protein 70 on the proliferation and apoptosis of A549 cells)

[0058] Its chemical structure is as follows: 5'-CGCAGAACACCGUGUUCGATT-3'(sense); 5'-UCGAACACGGUGUUCUGCGTT-3'(antisense),

[0059] Its sources are as follows: synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd.

[0060] LTPTT: Low-temperature PTT, low-temperature photothermal therapy

[0061] RNAi: RNA interference, please list the English abbreviations that appear in other places in the RNA interference manual and provide further explanation:

[0062] EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

[0063] NHS: N-hydroxysuccinimide

[0064] OD value: optical density value

[0065] DEPC: Diethyl pyrocarbonate

[0066] NC: non-cognate-siRNA

[0067] RPMI 1640: Roswell Park Memorial Institute developed cell culture medium

[0068] FBS: fatal bovine serum

[0069] PBS: phosphate buffer saline, phosphate buffered saline

[0070] MES: 2-morpholineethanesulfonic acid

[0071] MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

[0072] DMSO: dimethyl sulfoxide

[0073] CTAB: Cetyltrimethylammonium bromide

[0074] NS: Normal saline

[0075] Cy5: cyanine dye fluorescent labeling

[0076] ELISA: Enzyme-linked immunosorbent assay

[0077] RT-qPCR: Real-time quantitative reverse transcription-polymerase chain reaction

[0078] PI: Propidium bromide

[0079] The main advantages of the present invention are:

[0080] 1) The gold rod-based nano drug delivery system prepared in the present invention can respond to the microenvironment of the tumor site, release the chitosan-gene drug complex under the catalysis of the MMP enzyme in the tumor site, and achieve controlled release of gene drugs and efficient delivery to the deep level of the tumor;

[0081] 2) At the same time, through the regulatory effect of RNA interference technology, the tolerance problem of golden rod photothermal therapy can be solved, sustainable photothermal therapy under low temperature conditions can be achieved, and the photothermal therapy effect of the golden rod can be maximized. BRIEF DESCRIPTION OF THE DRAWINGS

[0082] Figure 1 .AGC / siRNA preparation route.

[0083] Note: AGC / siRNA is the abbreviation for Au-GPLGLAG-CS / HSP 70 siRNA.

[0084] Figure 2 .Schematic diagram of the in vivo mechanism of action of AGC / siRNA.

[0085] Figure 3 .A. Changes in particle size of Au, Au-GPLGLAG-COOH and AGC; B. Changes in Zeta potential of Au, Au-GPLGLAG-COOH and AGC; C. Transmission electron microscopy images of Au, Au-GPLGLAG-COOH and AGC.

[0086] Figure 4 .A. Gene loading rate of AGC vector; B. Agarose gel electrophoresis of free gene and AGC / siRNA against nuclease degradation; C. In vitro HSP 70 siRNA release curve; D. Temperature change diagram of AGC under near-infrared light irradiation of different powers; E. Photothermal repeatability diagram of AGC.

[0087] Figure 5 .A. Cellular uptake of free genome, AGC / siRNA without enzyme group and AGC / siRNA+MMP-2 enzyme group; B. Cellular uptake of AGC / siRNA+MMP-2 enzyme group at 4 hours; C. Tumor sphere penetration results of free genome, AGC / siRNA without enzyme group and AGC / siRNA+MMP-2 enzyme group.

[0088] Figure 6 .A and B. The safety of AGC vector and AGC / siRNA complex was evaluated by MTT method; C. Inter-group comparison of in vitro anti-cell proliferation results of different groups of AGC / siRNA after illumination.

[0089] Figure 7 .A. Real-time reverse transcription quantitative polymerase chain reaction was used to detect the HSP 70-mRNA level of 4T1 cells in different treatment groups; B. Enzyme-linked immunosorbent assay was used to detect the HSP 70 protein level of 4T1 cells in different treatment groups.

[0090] Note: NC is non-cognate negative control siRNA.

[0091] Figure 8 .A. Effect of AGC / siRNA on the apoptotic morphology of 4T1 cells; B. Flow cytometry was used to detect the apoptotic rate of 4T1 cells in each experimental group; C. Bar graph of apoptosis of 4T1 cells at different stages.

[0092] Fig. 9 . Flowchart of the experiment at different time points after BALB / c mice were inoculated with tumor cells.

[0093] Fig.10 .In vivo antitumor activity results of AGC / siRNA. A. Changes in tumor volume of BALB / c mice every three days; B. Images of mouse tumors removed the day after the last infrared irradiation; C. H&E staining of mouse tumor tissues in normal saline (blank control group), APC / NC group, APC / HSP 70siRNA group, and AGC / HSP 70siRNA group. (20×), (n=5).

[0094] Note: APC / NC is a complex formed by the co-incubation of Au-PEG-CS and NC, and APC / HSP 70 siRNA is a complex formed by the incubation of Au-PEG-CS and HSP 70 siRNA.

[0095] Fig.11 .A. H&E staining of various organs and tissues of mice in normal saline (blank control group), APC / NC group, APC / HSP 70 siRNA group and AGC / HSP70 siRNA group. (10×), (n=5). B. Ratio of weight of various organs to body weight of mice.

[0096] Dosage: The dosage of the blank control saline group was 0.05 mL / mouse; the dosage of the APC / NC group, APC / HSP 70 siRNA group and AGC / HSP 70 siRNA group was 0.05 mL of drug solution containing 40 μg of gold rod / mouse. DETAILED DESCRIPTION

[0097] In order to further illustrate the present invention, a series of examples are given below. These examples are completely illustrative, and they are only used to specifically describe the present invention and should not be understood as limiting the present invention.

[0098] Example 1 Preparation of AGC / siRNA

[0099] Preparation of gold nanorods

[0100] Preparation of gold nanorods by seed growth method

[0101] Preparation of gold nanoparticle seed solution:

[0102] Prepare 3 mL of 0.1 M CTAB solution with deionized water, add 0.1 mL of 0.01 M chloroauric acid at room temperature and mix well. Add 0.24 mL of 0.01 M ice-cold sodium borohydride under vigorous stirring (1500 rpm), and activate in a water bath at 28°C in the dark for 60 min.

[0103] Preparation of growth solution:

[0104] Prepare 40mL of 0.1M CTAB solution with deionized water, add 2mL of 0.01M chloroauric acid to it at room temperature and mix well. Add 400μL of 0.01M silver nitrate solution, 400μL of 0.1M ascorbic acid solution and 1.6mL of 1M dilute hydrochloric acid in sequence and mix well. Finally, add 100μL of seed solution. Seal with parafilm, wrap with tin foil, and place in a 28℃ water bath in the dark overnight.

[0105] The UV absorption spectrum was measured: the short diameter peak was about 520nm, and the long diameter peak was about 813nm. The particle size was measured by a particle size analyzer: the short diameter was 4.105±1.044nm, and the long diameter was 71.42±25.47nm. The Zeta potential was 35.7mV.

[0106] Preparation of Au-GPLGLAG-COOH

[0107] When the gold nanorods are not subsequently modified, the synthesized gold nanorods can be directly stored in a 4°C refrigerator. In the subsequent reaction, they are concentrated at a ratio of four times and used immediately after concentration. Use a pipette to draw 800 μL of the original gold nanorod solution into a 2mL centrifuge tube, centrifuge at 9000 rpm for 12 minutes, carefully discard 600 μL of the supernatant with a pipette, and resuspend to achieve the initial concentration of the gold nanorods.

[0108] Weigh about 6 mg of Mpa-GPLGLAG-COOH polypeptide and dissolve it thoroughly with 1 mL of deionized water by ultrasonication, then add the rotor. Add 200 μL of concentrated gold nanorod solution dropwise under magnetic stirring in a 25°C water bath, and react for 24 hours in the dark.

[0109] After the reaction is terminated, centrifuge at 9000 rpm for 10 min, discard 1 mL of supernatant, add 800 μL of deionized water to resuspend, centrifuge at 9000 rpm for 10 min, discard supernatant, add 1 mL of deionized water to resuspend, centrifuge at 9000 rpm for 10 min, and discard all supernatant.

[0110] The particle size measured by the particle size analyzer is: short diameter: 35.91±7.953nm, long diameter: 215.3±77.74nm. Zeta potential is -12.4mV.

[0111] Preparation of AGC

[0112] Chitosan (CS) is insoluble in water but soluble in acidic solution, so 0.1M MES buffer solution is used to dissolve it. Weigh 4mg of chitosan and dissolve it in 1mL of 0.1M MES solution, and ultrasonicate for 30min. Centrifuge the AuNRs-GPLGLAG-COOH aqueous solution at 9000rpm for 10min, and remove the supernatant. Then add the ultrasonicated chitosan MES solution to the above precipitate, and continue ultrasonicating for 1h. Weigh 3mg of EDC and NHS respectively, and dissolve them in 0.2mL of MES solution respectively. After 1h, slowly add 0.2mL of NHS solution to the system, then slowly add 0.2mL of EDC solution, and finally add 0.1mL of MES solution to make the total solution system 1.5mL. Continue ultrasonicating for 3h, then transfer it to a magnetic stirrer and stir at 25℃ in the dark for 19h.

[0113] After the reaction stops, centrifuge at 9000 rpm for 10 minutes, discard the supernatant, wash twice with 1% acetic acid solution and once with pure water to convert the system into neutral, and finally resuspend with deionized water to obtain the AGC carrier.

[0114] The particle size measured by the particle size analyzer is: short diameter: 14.48±3.205nm, long diameter: 164.9±109.5nm. Zeta potential is 42.7mV.

[0115] Preparation of AGC / siRNA

[0116] 1OD HSP 70 siRNA (33 μg) was dissolved in 250 μL DEPC water to prepare a 10 μmol / L HSP 70 siRNA solution. 1 μL siRNA was mixed with different volumes of AGC and incubated overnight at room temperature on a shaker to obtain an AGC / siRNA transfection complex.

[0117] Determination of the amount of HSP 70 siRNA loaded in AGC / siRNA

[0118] Sample preparation: 1OD HSP 70 siRNA (33 μg) was dissolved in 250 μL DEPC water to prepare a 10 μmol / L HSP70 siRNA solution. 1 μL siRNA was mixed with AGC in different volume ratios (v / v = 1:4, 1:10, 1:20, 1:40, 1:100, 1:160) and incubated for 14 h at room temperature on a shaker to obtain AGC / siRNA transfection complexes in different ratios.

[0119] Experimental steps: Centrifuge the AGC / siRNA transfection complexes with different volume ratios at 13,000 rpm for 10 minutes, dilute the supernatant to 2 mL, and measure the fluorescence value of the supernatant using a fluorescence spectrophotometer. Using the Cy5 fluorescence standard curve, calculate the concentration of free genes in the supernatant, and indirectly calculate the gene loading capacity of the vector.

[0120] The experimental results show that the amount of free genes after different volumes of AGC vectors are loaded with genes can be determined by the obtained gene fluorescence standard curve. In the experiment, the volume of 10μM Cy5-HSP 70siRNA gene was fixed at 1μL, and the volume of AGC vector solution was continuously increased. Figure 4 (A) It can be seen that as the volume of the AGC vector increases, the gene loading rate tends to be flat in the range of 50 to 150 μL, indicating that the loading capacity of the AGC vector has reached saturation. Therefore, the present invention finally determines the volume of the AGC vector to be 100 μL to ensure that the gene can be effectively loaded.

[0121] Example 2 Determination of the Nanostructure of AGC

[0122] Experimental method: Take a small amount of Au, Au-GPLGLAG-COOH and AGC solution and dilute it appropriately, take 20μL onto a copper mesh covered with a carbon film, place the copper mesh in a 37℃ oven and dry it for at least 48h to allow the sample to be fully deposited, concentrated and dried on the copper mesh, and observe its morphology with a transmission electron microscope 2100 and record pictures.

[0123] The experimental results are as follows Figure 3 As shown in (C), the long diameter of the unmodified gold nanorods is about 70nm, and the overall structure is relatively uniform. The gold nanorods modified with the Mpa-GPLGLAG polypeptide showed mutual adhesion and aggregation, but they can be distinguished to have a rod-like structure. After modification with CS, the dispersion of the carrier is improved, and a halo appears around the gold nanorods, indicating that a modification layer has been formed on the surface of the gold nanorods.

[0124] Example 3 Determination of the temperature rise of AGC under near-infrared light irradiation of different powers

[0125] The experimental method for different power temperature rise conditions was to add 500μL of AGC into a 2mL centrifuge tube, fix the distance between the 808nm infrared laser probe and the centrifuge tube at 1cm, and the distance between the thermal imager and the centrifuge tube at 14cm. The current of the 808nm infrared laser was changed to achieve power changes, and the temperature rise of the AGC solution was recorded every 30s.

[0126] Experimental results The present invention uses a 808nm near-infrared laser and a thermal imager to record the temperature rise of the AGC at different powers. During the experiment, the distance between the centrifuge tube and the probe and the distance between the thermal imager and the centrifuge tube are fixed. Figure 4 (D) It can be seen that as the near-infrared light irradiation power increases, the temperature rise caused by the carrier AGC increases. And the temperature rise is only related to the photothermal conversion properties of the AGC itself, and has nothing to do with the PBS solvent. It can be seen from the figure that the temperature rise of the PBS group under higher-power near-infrared light irradiation is not obvious. All groups will reach a plateau period of temperature rise after a certain period of time. The experimental power finally determined for this project is 1.911W / cm 2 The reason is that this irradiation power can rapidly heat up the AGC for photothermal therapy without causing damage to normal tissues and cells.

[0127] Example 4 Determination of the photothermal conversion repeatability of AGC

[0128] The experimental method for photothermal conversion repeatability is to add 500μL of AGC into a 2mL centrifuge tube, fix the distance between the 808nm infrared laser probe and the centrifuge tube at 1cm, the distance between the thermal imager and the centrifuge tube at 14cm, the current of the 808nm infrared laser at 2.18A, and record the process of the AGC solution heating up to a steady state every 20s, then stop irradiation and cool down naturally to room temperature.

[0129] The experimental results used an 808nm near-infrared laser and a thermal imager to record the repeatability of the AGC's photothermal conversion five times. Figure 4 (E) It can be seen that the AGC carrier prepared in the experiment has good photothermal conversion repeatability, rapid heating, and the temperature can be maintained for about 20 minutes.

[0130] Example 5 Determination of the in vitro RNase A degradation resistance of AGC / siRNA

[0131] Experimental method: Naked siRNA group and AGC / siRNA group were set up. 1 μL HSP70siRNA was dissolved in 100 μL DEPC water and AGC / siRNA was obtained by co-incubating 1 μL 10 μmol / L HSP 70siRNA and 100 μL AGC overnight to ensure that the total volume of the two solutions was consistent. According to the time point, the samples were divided into different centrifuge tubes, 10 μL of sample solution was taken from each tube, and 4 μL of RNase A solution (10 μg / mL) was added respectively. After being fully mixed with a micro-vortex oscillator, the samples were placed in a 37°C oven for 30 minutes.

[0132] When the set time points (0h, 1h, 2h, 3h, 4h, 5h, 6h, 8h) are stopped, 4μL proteinase K solution (5mg / mL) is added to the centrifuge tubes to stop RNase A degradation of siRNA, and incubated at 37°C for 30min. Then add 20μL heparin sodium (0.8mg / mL) and shake on a shaker at room temperature for 30min to fully replace the siRNA in the carrier. Finally, take out 10μL sample solution, add 2μL RNA loading buffer (5×), mix well, and wait for loading. After electrophoresis, the in vitro anti-RNase A degradation of GCE / siRNA is judged according to the intensity of the fluorescent bands at each time point.

[0133] Experimental results The experimental results are as follows Figure 4 (B) shows that the first figure shows that free HSP 70 siRNA without AGC carrier loading can be completely enzymatically digested within 5 minutes under the action of nuclease. The second figure shows that HSP 70 siRNA loaded with AGC carrier can still produce brighter bands after 8 hours of co-action with nuclease, indicating that AGC carrier can effectively load HSP 70 siRNA and play a good protective role on genes.

[0134] Example 6 Investigating the in vitro release ability of HSP 70 siRNA gene using a fluorescence spectrophotometer

[0135] Experimental method: 1 μL 10 μmol / L Cy5-labeled HSP 70 siRNA was co-incubated with 100 μL AGC vector on a shaker overnight. Then centrifuged at 13000 rpm for 10 min, washed 3 times with deionized water, discarded the supernatant, and resuspended the washed precipitate with 200 μL DEPC water. Take 50 μL of the precipitate resuspension, add 450 μL DEPC water, and then add 0.5 μL 0.25 μg / μL MMP-2 enzyme. After shaking on a shaker for 30 min, the fluorescence intensity-time image of the solution was scanned with a fluorescence spectrophotometer to determine the in vitro release ability of the gene.

[0136] The experimental results are as follows Figure 4 As shown in (C), the release rate of HSP 70 siRNA in the experimental group with the addition of MMP-2 began to stabilize after 2 hours and the release rate reached 79%, but HSP 70 siRNA was almost not released in the control group without the addition of MMP-2. The above results show that after adding the matrix metalloproteinase-2 specific hydrolysis sensitive polypeptide overexpressed in the tumor microenvironment, the larger AGC carrier can be converted into small nanoparticles, thereby improving the in vitro release effect of HSP 70 siRNA.

[0137] Example 6 Laser confocal microscopy to investigate the cellular uptake of AGC / siRNA by 4T1 cells Experimental method

[0138] 1) Cell culture: Mouse triple-negative breast cancer 4T1 cells were cultured in RPMI 1640 medium (10% FBS, 1% penicillin and streptomycin) in a 37°C, 5% CO2 cell culture incubator. The cells were passaged 2-3 times a week until the confluence rate reached 80%.

[0139] 2) Laser confocal microscopy measurement: 1×10 5 4T1 cells were seeded in a laser confocal microplate with an inner diameter of 20 mm and cultured at 37°C and 5% CO2 for 24 h. After the cells adhered to the wall, the cells were treated with 500 μL of blank medium containing drugs prepared in the blank control group, free genome, AGC / siRNA group without enzyme, and AGC / siRNA group with enzyme, respectively. After 4 h of transfection, the drug-containing medium was discarded, and the cells were washed three times with PBS. 1 mL of Hoechst 33342 working solution was added to each dish, incubated for 15 min, and then discarded. The dishes were washed three times with PBS, and finally a small amount of PBS was reserved in each dish to prevent the slices from drying. The plates were observed and photographed under a laser confocal microscope (Leica, TCSSP5, Germany).

[0140] Experimental results: The present invention uses Hoechst 33342 to stain the cell nucleus, and the red fluorescence of Cy5-siRNA is used to determine the uptake of the gene by the cell. Figure 5 As shown in (A), no red fluorescence appeared in the blank control group and the free HSP 70 siRNA group within 4 hours, indicating that the free siRNA without carrier loading could not enter the 4T1 cells within 4 hours; however, a small amount of red fluorescence surrounded the cells and the nucleus in the experimental group loaded with AGC carrier but without adding MMP-2 for enzymatic hydrolysis, indicating that the AGC carrier can load genes into cells, but only a small part can approach the cells before being converted into small particles by enzymatic hydrolysis; more red fluorescence can be seen in the experimental group loaded with AGC and added with MMP-2 for enzymatic hydrolysis around the nucleus and a small part can enter the nucleus, indicating that the AGC carrier is converted into small particles after MMP-2 enzymatic hydrolysis, and can effectively load siRNA into cells to exert RNA interference.

[0141] Example 7 Evaluation of the effect of AGC / siRNA silencing HSP 70 gene by real-time reverse transcription quantitative polymerase chain reaction

[0142] Experimental methods

[0143] 1) Cell culture and transfection: 500 μL of cell solution with a concentration of 2×10 5 / mL of 4T1 cell suspension, incubate in a 37℃, 5% CO2 incubator, and wait for 24 hours for the cells to adhere to the wall. Use a pipette to carefully discard the complete culture medium in each well, and be careful not to suck away dead cells as much as possible. Then add 0.5mL of blank culture medium containing drugs to each group. A blank control group needs to be set up, and only 0.5mL of blank culture medium is added to the well. Each group needs to set up 3 replicate wells. Place the 24-well plate in a 37℃, 5% CO2 incubator and culture for 6 hours. After 6 hours, use a pipette to carefully discard the drug-containing culture medium in each well, replace it with 0.5mL of complete culture medium, and continue to culture in the cell culture incubator for 42 hours.

[0144] 2) Extraction of total cellular RNA: Wipe the work surface with RNase A remover before the experiment and use enzyme-free centrifuge tubes and pipette tips.

[0145] Take the 24-well plate out of the cell culture incubator and carefully discard the culture solution. Do not let the tip of the pipette touch the bottom of the well. Add 0.25mL Trizol lysis solution to each well and gently shake the 24-well plate to allow the lysis solution to fully contact the cells. Use a pipette to gently blow each well to fully lyse the cells in the well. When the lysis solution in each well becomes slightly viscous, it means that the lysis is relatively complete. The entire blowing and lysis time is 10 to 15 minutes. Then, use a pipette to transfer the liquid in the well to an enzyme-free centrifuge tube and let it stand for 5 minutes to allow the nucleic acid-protein complex to fully decompose.

[0146] Use a pipette to add 0.05 mL of chloroform to each enzyme-free centrifuge tube and vortex vigorously for 15 seconds. After the liquid is fully mixed, let it stand at room temperature for 3 minutes and centrifuge at 4°C, 12000 rpm, for 15 minutes. After centrifugation, the suspension is divided into three layers: the lower layer is the red phenol-chloroform layer, the middle layer is the white protein complex, and the top layer is the aqueous phase, in which RNA exists.

[0147] Use a pipette to transfer the upper aqueous phase to another enzyme-free centrifuge tube, add 0.125 mL of isopropanol to each tube, mix thoroughly, let stand at room temperature for 10 minutes, and then centrifuge at 4°C, 12,000 rpm, for 15 minutes. After centrifugation, a white precipitate can be seen at the bottom of the centrifuge tube.

[0148] Carefully discard the supernatant and add 0.25 mL of 75% ethanol (V 乙醇 / V DEPC =3:1). Wash the RNA precipitate, shake and mix, centrifuge at 4°C, 12000rpm for 20min, repeat the washing three times, discard the supernatant, and dry in a fume hood for later use.

[0149] After the precipitate is dried, absorb 20 μL of DEPC water to resuspend the RNA, blow and beat repeatedly, and sonicate to completely dissolve the RNA. Place it in a 55°C water bath for 15 minutes, and then let it stand at room temperature for 20 minutes. It can be stored in a -80°C refrigerator.

[0150] After RNA extraction, RNA purity and concentration were measured. First, the Nanodrop-1000 was cleaned and calibrated with DEPC water. After calibration, 2 μL of RNA aqueous solution was dripped onto the measuring arm, and the nucleic acid RNA-measure was selected to measure the OD 260 / OD 280 value and concentration value.

[0151] 3) Reverse transcription:

[0152] Sample requirements: The loading amount of reverse transcribed RNA is 2 μg. The RNA concentration is measured by Nanodrop-1000, and the volume of RNA aqueous solution required for reverse transcription is calculated.

[0153] Preparation of reverse transcription primer working solution: In order to save reverse transcription reagents and obtain more stable results, HSP 70 target gene reverse transcription primer (10μM 10μL) and internal reference GAPDH reverse transcription primer (10μM 10μL) were mixed together, and 80μL RNase free H2O was added to dilute 10 times to 1μM reverse transcription primer working solution. One reverse transcription reaction can simultaneously obtain the target gene and internal reference gene quantitative PCR cDNA templates, and obtain the same effect as separate reverse transcription.

[0154] Preparation of gene-specific reverse transcription reaction system:

[0155] ① Mix the following reagents in an RNase-free centrifuge tube for pre-denaturation:

[0156]

[0157] ② Heat in a water bath to 70℃ for 5 minutes, then place on ice immediately.

[0158] ③ Mix other reagents according to the 20 μL reverse transcription reaction system provided in the table below.

[0159]

[0160] All reagents, reaction mixtures and samples should be placed on ice. Before the reverse transcription reaction, all reagents except the reverse transcriptase must be mixed. You can flick the tube wall containing the reagents with your fingers. The reverse transcription mix can be pipetted several times with a pipette. Do not use an oscillator.

[0161] ④ Run the mRNA reverse transcription program using GeneAmp PCR System 9700: 42℃45min, 85℃5min, and store at 4℃. After the reverse transcription reaction at 85℃5min, take out the cDNA product immediately and quickly cool it on ice. All subsequent steps are carried out on ice. Do not remove the cDNA product from the ice casually.

[0162] ⑤ Mix the cDNA and take 1 μL (20 μL system) as a template for quantitative PCR. If the cDNA is not used temporarily, it can be stored at -20℃. It can remain stable within three days and can be frozen at -80℃ for long-term storage.

[0163] 4) RT-PCR

[0164] Preparation of quantitative PCR reaction mix: Mix well and centrifuge at low speed before use to ensure that 2× Real-time PCR MasterMix, 50× ROX Reference Dye, primers, and template are completely dissolved and all reagents are at the bottom of the tube. Place on ice to prepare the Real Time PCR reaction solution.

[0165] After sealing the PCR reaction tube with a sealing film, put it into the Real-Time PCR System 7500 and set the conditions as follows: pre-denaturation: 95°C for 3 min, Cycle (1 cycle); PCR reaction: 95°C for 12 s, 62°C for 40 s, Cycle (40 cycles) for amplification.

[0166] Using 2^ -△△Ct The data obtained by RT-PCR were processed by this method and the results are shown in the table below.

[0167] Experimental Results

[0168] Table 1. Relative amount of HSP 70-mRNA in 4T1 cells under the action of AGC / siRNA (n=3)

[0169]

[0170] from Figure 7(A) It can be seen that there is no significant difference in the relative level of HSP 70-mRNA between the blank control group and the free genome (P>0.05), which is not statistically significant, indicating that the HSP 70 siRNA of the free genome cannot effectively enter the 4T1 cells to downregulate the gene expression of HSP 70 and cannot play an RNA interference role; while the relative level of HSP 70-mRNA in the AGC / siRNA group is lower than that in the blank control group (P<0.01), which is statistically significant, indicating that using AGC as a gene delivery carrier of siRNA can increase the amount of siRNA entering cells to a certain extent, downregulate the gene expression of HSP 70, and play a certain degree of RNA interference. However, the effect is still relatively weak, with a downregulation rate of 16.51%±1.44%.

[0171] The final experimental group of the present invention is the AGC / siRNA group hydrolyzed by MMP-2. Compared with the blank control group, the relative levels of HSP 70-mRNA in the experimental group and the Lipo / siRNA positive control group are significantly different (P<0.01), indicating that both groups of experiments can effectively reduce the expression of HSP 70-mRNA, and the effect of the hydrolysis experimental group is better than that of the positive control group, with the down-regulation rates of 44.02%±1.86% and 35.31%±5.03%, respectively. The above experimental results show that the AGC / siRNA hydrolyzed by MMP-2 can efficiently enter the cells and significantly down-regulate the expression of mRNA, thereby exerting the RNA interference effect.

[0172] Example 8 Evaluation of the effect of AGC / siRNA on down-regulating HSP 70 protein expression by ELISA

[0173] Experimental methods

[0174] 1) Cell culture and transfection: 500 μL of cell solution with a concentration of 2×10 5 / mL of 4T1 cell suspension, incubate in a 37℃, 5% CO2 incubator, and wait for 24 hours for the cells to adhere to the wall. Use a pipette to carefully discard the complete culture medium in each well, and be careful not to suck away dead cells as much as possible. Then add 0.5mL of blank culture medium containing drugs to each group. A blank control group needs to be set up, and only 0.5mL of blank culture medium is added to the well. Each group needs to set up 3 replicate wells. Place the 24-well plate in a 37℃, 5% CO2 incubator and culture for 6 hours. After 6 hours, use a pipette to carefully discard the drug-containing culture medium in each well, replace it with 0.5mL of complete culture medium, and continue to culture in the cell culture incubator for 42 hours.

[0175] 2) Determination of total protein concentration in culture supernatant using BCA Protein Assay Kit

[0176] Use the BCA protein quantification kit to draw a standard curve according to the instructions and determine the concentration of each group of protein samples.

[0177] 3) ELISA kit to determine the content of HSP 70 in sample protein

[0178] Dilution of standard: The ELISA kit provides one original standard. Use standard diluent to perform gradient dilution of the original standard to prepare a series of standard dilutions with concentrations of 30ng / L, 60ng / L, 120ng / L, 240ng / L and 480ng / L.

[0179] Sample addition: There are blank wells (blank control wells do not add samples and enzyme-labeled reagents, and the rest of the steps are the same), standard wells, and test sample wells. Accurately add 50μL of the standard sample to the enzyme-labeled plate, add 40μL of sample diluent to the test sample well, and then add 10μL of the test sample (the final sample dilution is 5 times). When adding samples, add the sample to the bottom of the well of the enzyme-labeled plate, try not to touch the well wall, and gently shake to mix.

[0180] Incubation: Seal the plate with a sealing film and incubate in a 37°C incubator for 30 min.

[0181] Solution preparation: Dilute the 20-fold concentrated washing solution 20-fold with distilled water for later use.

[0182] Washing: Carefully peel off the sealing film, discard the liquid, spin dry, fill each well with washing solution, let it stand for 30 seconds and then discard, repeat this 5 times, and pat dry on kitchen paper.

[0183] Add enzyme: Add 50 μL of enzyme-labeled reagent to each well, except for the blank well. Subsequent incubation and washing are the same as above.

[0184] Color development: First add 50 μL of color developer A to each well, then add 50 μL of color developer B, gently shake to mix, and develop the color at 37°C in the dark for 10 min.

[0185] Stop: Add 50 μL of stop solution to each well to stop the reaction (the blue color quickly turns to yellow).

[0186] Determination: Use the blank well as zero setting, and measure the absorbance (OD value) of each well in sequence at a wavelength of 450nm. The determination should be carried out within 15 minutes after adding the stop solution.

[0187] Experimental Results

[0188] Table 1. Relative amount of HSP 70 protein in 4T1 cells under the action of AGC / siRNA (n=3)

[0189]

[0190] from Figure 7 (B) It can be seen that there was no significant difference in the relative level of HSP 70 protein between the blank control group and the free genome (P>0.05), which was not statistically significant, indicating that the free genome could not downregulate the expression of HSP 70 protein after administration; while the relative level of HSP 70 protein in the AGC / siRNA group was lower than that in the blank control group (P<0.01), which was statistically significant, indicating that this group of drugs could downregulate the expression of HSP 70 protein to a certain extent, with a downregulation rate of 24.97%±1.42%.

[0191] Compared with the blank control group, the relative levels of HSP 70 protein in the MMP-2 enzymatically hydrolyzed AGC / siRNA group and the Lipo / siRNA positive control group showed significant differences (P < 0.01), indicating that both groups of experiments can effectively reduce the expression of HSP 70 protein, and the effect of the enzymatic hydrolysis experimental group is better than that of the positive control group, with the downregulation rates of 42.68% ± 0.10% and 34.21% ± 2.76%, respectively.

[0192] Example 9 Evaluation of the cytotoxicity and tumor cell proliferation inhibition effects of AGC / siRNA

[0193] (1) Cytotoxicity experiment of AGC

[0194] Experimental methods

[0195] Take 4T1 cells in logarithmic phase and adjust the cell solution concentration to 8×10 4 / mL was inoculated in a 96-well plate, and the wells without cells were used as blank groups (zero wells), and the outermost circle of the 96-well plate was sealed with PBS buffer. Cultured in a 37°C, 5% CO2 incubator for 24 hours, and after the cells adhered to the wall, different concentrations of carrier solutions (4μg / mL, 8μg / mL, 24μg / mL, 48μg / mL, 80μg / mL) were added to the 96-well plate, 10μL was added to each well, and 5 replicates were set. Then cultured in a 37°C, 5% CO2 incubator for 24 hours. No drugs were added to the blank group and the control group.

[0196] After 24 hours of culture, add 25 μL of MTT (5 mg / mL) working solution to each well, shake the 96-well plate gently back and forth to mix the solution evenly, and incubate it in a 37°C, 5% CO2 incubator for 4 hours. After 4 hours, carefully place the 96-well plate in a centrifuge for centrifugation (1,000×g, 5min), discard the supernatant, add 150 μL of DMSO solution to each well, and place it on a micro-oscillator to fully oscillate evenly. Use an ELISA reader, set the detection wavelength to 570nm, measure the OD value of each well of the 96-well plate, and calculate the cell survival rate in each well. Use the formula: The above experimental steps were repeated three times.

[0197] Experimental Results

[0198] When the reaction process is monitored by Zeta potential, it can be found that the synthesized AGC carrier has a strong positive charge, which will cause the negatively charged cell membrane to rupture and cause the death of 4T1 cells. Figure 6 As shown in (A), the cell activity of all AGC vector-administered groups was significantly reduced and positively correlated with the AGC concentration, but the difference was not too large. Therefore, there was a significant difference between the drug-administered group and the blank control group, indicating that the positively charged AGC vector itself can produce toxic effects on 4T1 cells.

[0199] (2) Cytotoxicity experiment of AGC / siRNA

[0200] Experimental methods

[0201] Take 4T1 cells in logarithmic phase and adjust the cell solution concentration to 8×10 4 / mL was inoculated in a 96-well plate, and the blank group (zero well) without adding cells was sealed with PBS buffer in the outermost circle of the 96-well plate. Cultured in a 37°C, 5% CO2 incubator for 24 hours, and after the cells adhered to the wall, the carrier solution (10nM, 20nM, 60nM, 120nM, 200nM) of different gene concentrations, AGC / NC, AGC / siRNA, and AGC / siRNA drugs hydrolyzed by MMP-2 for 1 hour were added to the 96-well plate, 10μL was added to each well, and 5 replicates were set. Then cultured in a 37°C, 5% CO2 incubator for 24 hours. No drugs were added to the blank group and the control group.

[0202] After 24 hours of culture, add 25 μL of MTT (5 mg / mL) working solution to each well, shake the 96-well plate gently back and forth to mix the solution evenly, and incubate it in a 37°C, 5% CO2 incubator for 4 hours. After 4 hours, carefully place the 96-well plate in a centrifuge for centrifugation (1,000×g, 5min), discard the supernatant, add 150 μL of DMSO solution to each well, and place it on a micro-oscillator to fully oscillate evenly. Use an ELISA reader, set the detection wavelength to 570nm, measure the OD value of each well of the 96-well plate, and calculate the cell survival rate in each well. Use the formula: The above experimental steps were repeated three times.

[0203] Experimental Results

[0204] Although the AGC vector has a killing effect on 4T1 cells, the present invention uses AGC as a gene delivery vector for HSP 70 siRNA, so the cytotoxicity of AGC loaded with siRNA was evaluated. Figure 6As shown in (B), with the continuous increase of AGC concentration, the survival rate of 4T1 cells in each group did not decrease significantly. And when the maximum AGC concentration was 80μg / mL, the cell survival rate of 4T1 was still around 90%, and there was no significant difference between the experimental groups and the blank control group (P>0.05), so it was not statistically significant. The results of this experiment show that the AGC / siRNA complex has little effect on the survival rate of 4T1 cells, and it has no obvious toxicity to cells, which eliminates interference with the subsequent anti-cell proliferation effect of AGC / siRNA after illumination, indicating that the AGC carrier can become a safe delivery carrier for HSP 70siRNA for subsequent experiments.

[0205] (3) Effect of AGC / siRNA on the inhibition of 4T1 cell proliferation after illumination

[0206] Experimental methods

[0207] Take 4T1 cells in logarithmic phase and adjust the cell solution concentration to 8×10 4 / mL was inoculated in a 96-well plate, and the blank group (zero well) without adding cells was used as the blank group, and the outermost circle of the 96-well plate was sealed with PBS buffer. Cultured in a 37°C, 5% CO2 incubator for 24 hours. After the cells adhered to the wall, the carrier solutions with different gene concentrations (10nM, 20nM, 60nM, 120nM, 200nM), AGC / NC, AGC / siRNA, and AGC / siRNA drugs hydrolyzed with MMP-2 for 1h were added to the 96-well plate, 10μL was added to each well, and 5 replicate wells were set. Then cultured in a 37°C, 5% CO2 incubator for 6 hours. After 6 hours, each well was irradiated with 808nm near-infrared light. The current of the 808nm near-infrared laser was set to 2.18A, which is converted to a power of 1.911W / cm 2 Each well was irradiated for 3 min. After all irradiation was completed, the cells were cultured in a 37°C, 5% CO2 incubator for 18 h.

[0208] After 18 hours, add 25 μL of MTT working solution to each well, incubate in a 37°C, 5% CO2 incubator for 4 hours, carefully place the 96-well plate in a centrifuge, discard the supernatant, add 150 μL of DMSO solution to each well, and place it on a micro-oscillator to fully oscillate. Use an ELISA reader, set the detection wavelength to 570 nm, measure the OD value of each well of the 96-well plate, and calculate the cell survival rate in each well. Repeat the above experimental steps three times.

[0209] Experimental Results

[0210] The in vitro anti-cell proliferation effect of AGC / siRNA in different groups after illumination was evaluated by MTT method. Figure 6As shown in (C), the comparison between different groups shows that the cell viability of the experimental group loaded with HSP 70 siRNA is slightly lower than that of the experimental group loaded with irrelevant siRNA, indicating that the large particles of AGC / siRNA complex can enter the cells in small amounts, and HSP70 siRNA can slightly reduce the level of heat shock protein, and the photothermal treatment effect of tumors has been slightly improved. However, after MMP-2 enzymatic hydrolysis, the AGC / siRNA complex is reduced from large to small, so that HSP 70 siRNA can be better taken up by cells, and the sensitivity of tumor cells to heat is reduced to a greater extent, greatly enhancing the photothermal treatment effect of gold nanorods.

[0211] Example 10 Evaluation of the apoptosis-promoting effect of AGC / siRNA on 4T1 cells

[0212] (1) Determination of cell apoptosis morphology by laser confocal microscopy

[0213] Experimental methods

[0214] Take 1×10 4T1 cells in logarithmic growth phase 5 100 μL / mL was inoculated into a glass-bottomed culture dish with an inner diameter of 20 mm and cultured in a 37°C, 5% CO2 incubator for 24 h. Take out the confocal dish from the carbon dioxide incubator, spray it with alcohol and place it on a clean bench. Tilt the dish by hand and use a pipette to suck away all the culture medium along the edge of the dish. Do not poke the bottom of the dish with the tip of the pipette. After discarding the culture medium of all the dishes, add 500 μL of drug-containing blank culture medium prepared according to the blank control group, AGC / NC group, AGC / siRNA without enzyme group and AGC / siRNA with enzyme group to the confocal dish and culture it in a 37°C, 5% CO2 incubator for 6 h.

[0215] After 6 hours, each confocal dish was irradiated with 808 nm near-infrared light. The current of the 808 nm near-infrared laser was set to 2.18 A, which converted to a power of 1.911 W / cm 2 , irradiate each dish for 3 minutes. After all irradiation is completed and the dish returns to room temperature, tilt the dish by hand and use a pipette to suck away all the drug-containing culture medium along the edge of the dish. Do not poke the bottom of the dish with the pipette tip. Then wash the dish with PBS and add 500 μL of complete culture medium to each dish, and continue to culture in a 37°C, 5% CO2 incubator for 18 hours.

[0216] Nuclear staining: Take out the confocal dish that has been cultured for 24 hours, spray it with alcohol and place it on a clean bench. Tilt the dish by hand and use a pipette to suck away all the culture medium along the edge of the dish. Do not poke the bottom of the dish with the tip of the pipette. Take 1mL PBS to rinse the dish and discard it. Then add 1mL PBS to soak the dish for 2 minutes and discard it. Add 500μL of 4% tissue cell fixative to each confocal dish and fix it in a 37℃, 5% CO2 incubator for 10-15 minutes. After fixation, rinse it three times with PBS. Add Hoechst33342 dissolved in PBS and incubate it in a carbon dioxide incubator for 10-15 minutes, then discard it and rinse it three times with PBS. Finally, add 200μL of PBS and observe it under a laser confocal microscope.

[0217] Experimental Results

[0218] The cell nuclei of each experimental group were stained with Hoechst 33342 dye, and the morphological changes of the cell nuclei of each experimental group after drug administration were observed using an inverted laser confocal microscope. Figure 8 As shown in (A), the nuclei of the blank control group were round and the chromatin was dense; the nuclei of the AGC / NC group were irregular after photothermal killing; the chromatin of the AGC / siRNA group became smaller and the edges were loose after photothermal treatment; the nuclei of the MMP-2 enzymatic group were lysed and shrunken into fragments, showing a more serious apoptotic morphology. The comparison between the above experimental groups shows that the MMP-2-specific enzymatic AGC / siRNA anti-tumor drug prepared in this project can inhibit the production of HSP 70 from the gene level through RNA interference after entering the cell with HSP 70 siRNA, thereby enhancing the photothermal efficacy of gold nanorods.

[0219] (2) Detection of cell apoptosis rate by flow cytometry

[0220] Experimental methods

[0221] Take the AGC / NC group, the AGC / siRNA group without enzyme, and the AGC / siRNA group with enzyme after 24 hours of light transfection, collect them in a centrifuge tube after trypsin digestion, and then wash each group of cells twice with PBS buffer precooled at 4°C. Add 195μL Annexin V-FITC binding solution to each tube of cells in the blank control group and each experimental group and gently resuspend the cells. Then add 5μL Annexin V-FITC to each tube and mix gently. Then add 10μL propidium iodide staining solution to each tube and mix gently. Finally, incubate at room temperature in the dark for 20 minutes, add 300μL binding buffer to make the total sample volume reach 500μL. Then place the centrifuge tube in an ice bath, use aluminum foil to avoid light, and detect within 1 hour. Set the excitation wavelength to 488nm and the emission wavelength to 530nm, and calculate the apoptosis rate of 4T1 cells in each group. Repeat the experiment three times.

[0222] Experimental Results

[0223] like Figure 8 As shown in (C), the enzymatically hydrolyzed AGC / siRNA group significantly increased the apoptosis rate of 4T1 cells compared with the AGC / NC group and the AGC / siRNA group, indicating that the enzymatically hydrolyzed AGC / siRNA group promoted the apoptosis of 4T1 tumor cells by utilizing the synergistic effect of photothermal therapy and gene therapy.

[0224] Example 11 Evaluation of the tumor sphere penetration of AGC / siRNA

[0225] Experimental methods

[0226] 1) 4T1 tumor sphere culture

[0227] Use serum-free RPMI1640 blank medium to disperse 2% low-melting point agarose (2g / 100mL), sterilize it in the agar melting mode of the autoclave, and take it out immediately when the temperature drops to about 90°C. Wrap the 15mL centrifuge tube with tin foil and cotton, and spread the 96-well plate as soon as possible. Add 100μL of melted low-melting point agarose to each well of the 96-well plate, do not touch the well wall, and do not generate bubbles. After all are spread, place it on the clean bench and irradiate it with ultraviolet light for 30 minutes.

[0228] Take 4T1 cells in the logarithmic growth phase and dilute them to 1000 cells / 100μL with DMEM complete medium. Inoculate 100μL of the diluted cell suspension in each well of a 96-well plate and then culture in a 37℃, 5% CO2 incubator. Do not move or observe within one week, and do not change the medium. After one week, when the medium turns yellow, replace the DMEM complete medium. After culturing the tumor spheres for 10 days, the experiment can be carried out.

[0229] 2) Drug administration and dyeing

[0230] Drug administration: Irradiate the clean bench with UV light for 30 minutes. When using the clean bench, wipe the table with alcohol cotton balls before starting the experiment. First, determine the specific location of the drug-administered tumor spheres by observing under an inverted microscope and mark them. Add all the drug preparations of the negative control group, experimental group 1, and experimental group 2 directly into the corresponding wells and culture them in a 37°C, 5% CO2 incubator for 24 hours.

[0231] Nuclear staining: Take the 96-well plate out of the carbon dioxide incubator, and gently transfer each dosing group to a 1.5 mL centrifuge tube with a sterile dropper. The small white dots formed by the tumor spheres can be observed to settle to the bottom of the tube. Then use a pipette to remove as much of the drug-containing culture medium as possible, add PBS to wash 2 to 3 times, and add liquid as gently and slowly as possible to avoid dispersing the tumor spheres. Finally, use a dropper to transfer the PBS-infiltrated tumor spheres to a confocal dish, and then add 500 μL of Hoechst 33342 nuclear dye dissolved in live cell staining buffer. Incubate in a 37°C, 5% CO2 incubator for 15 to 20 minutes, and use a laser confocal microscope to observe all levels of the tumor spheres to determine the penetration depth of the gene.

[0232] Experimental Results

[0233] like Figure 5 As shown in (C), after the free HSP 70 siRNA group was co-incubated with the tumor spheres for 24 hours, some red fluorescence appeared in the peripheral area of ​​the tumor spheres and co-localized with the cell nucleus, indicating that the free gene could only enter the surface of the tumor spheres within 24 hours and could not penetrate the tumor spheres into the central area; the AGC / siRNA group that was not degraded by MMP-2 enzyme had only a few red fluorescence spots on the periphery of the tumor spheres, which was due to the large particle size of the vector-loaded gene, which prevented it from entering the tumor spheres; the AGC / siRNA group that was hydrolyzed by MMP-2 was full of red fluorescence throughout the tumor spheres, indicating that the genes in the experimental group hydrolyzed by MMP-2 could be delivered into the tumor spheres, and had strong penetration ability, and could exert RNA interference effects deep in the tumor spheres.

[0234] Example 12 Evaluation of the anti-tumor activity of AGC / siRNA in vivo

[0235] Experimental methods

[0236] 1) Establishment of transplanted tumor-bearing mouse model

[0237] 4T1 cells in the logarithmic growth phase were selected and digested with trypsin for 2 minutes. After the digestion was terminated with complete medium, the cells were centrifuged at 1500 rpm for 3 minutes and the supernatant was discarded. PBS was added to resuspend and wash once. The total number of cells was calculated using a cell counting plate. The cells were centrifuged at 1500 rpm for 3 minutes, the supernatant was discarded, and the precipitate was diluted with PBS to a cell concentration of 5×10 7 Each mouse was injected subcutaneously with 100 μL of cell suspension into the right buttock to establish a 4T1 tumor model. The long and short diameters of the tumor were measured with a vernier caliper and the formula (long diameter × short diameter) was used to calculate the tumor size. 2 ) / 2 to calculate the tumor volume. When the tumor volume reaches 100mm 3 Start medication at .

[0238] 2) Antitumor activity and histopathological observation of AGC / siRNA in tumor-bearing mice

[0239] The established mouse breast cancer 4T1 tumor-bearing mouse model was randomly divided into 4 groups (n=5): saline group, APC / NC group, APC / HSP 70siRNA group and APC / HSP 70siRNA group. The drugs were administered as follows: saline group: 0.05 mL saline was injected into each mouse; the dosage of APC / NC group, APC / HSP 70siRNA group and AGC / HSP 70siRNA group was 40 μg / mouse in 0.05 mL drug solution. After wiping the right hind hip of the mouse with alcohol, 0.05 mL was injected into each group of mice by paratumor injection, and the tumor site was irradiated with infrared light for 3 minutes on the second day, and then the drug was administered again every other day, for a total of 4 times. The weight of mice in each group was weighed before each administration, and the long and short diameters of the tumor were measured with a vernier caliper, and the tumor volume was calculated and recorded. After the last illumination, the mice in each group were anesthetized the next day, and the heart, liver, spleen, lung, kidney, and tumor were removed, weighed, photographed, and recorded. The tumor inhibition rate was calculated using the formula: HE staining was used to observe the pathological histology of mouse tumors and important organs in the body.

[0240] Experimental Results

[0241] Depend on Fig.10 (A) and Fig.10 (B) It can be clearly seen that the average tumor volume of the AGC / siRNA group was significantly lower than that of the saline group, and its average tumor volume was also lower than that of the APC / NC group and the APC / siRNA group. This indicates that the effect of combined photothermal and gene therapy on tumors in this experimental group is higher than that of photothermal therapy alone. Fig.10 (C) is a histopathological study of mouse tumor tissue after drug administration using H&E staining technology. It can be clearly seen that the tumor cells in the normal saline group are closely arranged and the living cells are darker in color; while the tumor cells in the APC / NC group and the APC / siRNA group begin to become loosely arranged, the cell gaps become larger, and there is a punctate necrosis; however, the cells in the AGC / siRNA experimental group show large areas of necrosis, the dead cells are lighter in color, and the cell apoptosis is more obvious, indicating that the tumor cells have been strongly inhibited in vivo.

[0242] HE staining results of important organs in mice, such as heart, liver, spleen, lung and kidney Fig.11 As shown in (A), no obvious pathological features were observed in the staining results of the heart, liver, spleen, lung, and kidney of each group, indicating that AGC / siRNA had no obvious toxicity to the important organs of mice after irradiation. Fig.11As shown in (B), there was no significant difference in organ weight ratio between each experimental group and the saline group, which further indicated that AGC / siRNA has high in vivo biosafety.

Claims

1. A gene drug delivery system for enhancing the effect of photothermal therapy of tumors, wherein the structure is Au-GPLGLAG-CS / HSP 70 siRNA; wherein: The Au-GPLGLAG-CS is a gene delivery vector specific for MMP-2 in the tumor microenvironment; the HSP70 siRNA is a gene drug that downregulates the expression of HSP 70. Wherein, the gene drug delivery system is prepared by incubating Au-GPLGLAG-CS and HSP 70 siRNA at a mass ratio of 27.58:1; The preparation method of Au-GPLGLAG-CS is as follows: AuNRs and Mpa-GPLGLAG-COOH are reacted to obtain Au-GPLGLAG-COOH, and then chitosan CS is connected to the polypeptide through an amide bond. Among them, the sequence of HSP 70 siRNA and its chemical structure are as follows: Sense strand: 5'-CGCAGAACACCGUGUUCGATT-3', Antisense strand: 5′-UCGAACACGGUGUUCUGCGTT-3′.

2. The gene drug delivery system according to claim 1, characterized in that The gene drug delivery system is a rod-shaped nanostructure.

3. The method for preparing the gene drug delivery system according to claim 1, comprising the following steps: Au-GPLGLAG-CS and HSP 70 siRNA were co-incubated with shaking on a shaker at room temperature overnight and centrifuged to obtain the product.

4. The preparation method according to claim 3, characterized in that: 33 μg 1 OD HSP 70 siRNA was dissolved in 250 μL DEPC water to prepare a 10 μmol / L HSP 70 siRNA solution; 1 μL HSP 70 siRNA and 100 μL Au-GPLGLAG-CS were mixed and incubated overnight at room temperature on a shaker.

5. The preparation method according to claim 3, characterized in that: The preparation method of Au-GPLGLAG-CS is as follows: 1) Preparation of gold nanoparticle seed solution Prepare 3 mL of 0.1 M CTAB solution with deionized water, add 0.1 mL of 0.01 M chloroauric acid to it at room temperature and mix well; add 0.24 mL of 0.01 M ice-cold sodium borohydride under stirring at 1500 rpm, and activate in a water bath at 28 °C in the dark for 60 min; 2) Preparation of growth solution Prepare 40 mL of 0.1 M CTAB solution with deionized water, add 2 mL of 0.01 M chloroauric acid to it at room temperature and mix well; add 400 μL of 0.01 M silver nitrate solution, 400 μL of 0.1 M ascorbic acid solution and 1.6 mL of 1 M dilute hydrochloric acid in sequence and mix well; finally add 100 μL of seed solution; seal with sealing film, wrap with tin foil, and stand in a 28 ℃ water bath in the dark overnight; 3) Concentration of gold nanorod solution Use a pipette to draw 800 μL of the growth solution into a 2 mL centrifuge tube, centrifuge at 9000 rpm for 12 min, carefully discard 600 μL of the supernatant with a pipette, and resuspend to obtain a concentrated solution of gold nanorods; 4) Preparation of AuNRs-GPLGLAG-COOH Weigh 6 mg of Mpa-GPLGLAG-COOH peptide and dissolve it thoroughly with 1 mL of deionized water by ultrasonication. Add 200 μL of concentrated gold nanorod solution dropwise under magnetic stirring in a 25 ℃ water bath and react for 24 h in the dark. After the reaction is terminated, centrifuge and discard the supernatant. 5) Preparation of AuNRs-GPLGLAG-CS Weigh 4 mg of chitosan and dissolve it in 1 mL of 0.1 M MES solution, and sonicate for 30 min; centrifuge the AuNRs-GPLGLAG-COOH aqueous solution at 9000 rpm for 10 min, and remove the supernatant; then add the sonicated chitosan MES solution to the AuNRs-GPLGLAG-COOH precipitate, and continue sonicating for 1 h; weigh 3 mg of EDC and NHS respectively, and dissolve them in 0.2 mL of MES solution respectively; after 1 h, first slowly add 0.2 mL of NHS solution to the system, then slowly add 0.2 mL of EDC solution, and finally add 0.1 mL of MES solution to make the total solution system 1.5 mL; continue sonicating for 3 h, then transfer it to a magnetic stirrer and stir it in the dark at 25 °C for 19 h; after the reaction stops, centrifuge it at 9000 rpm for 10 min, and discard the supernatant; use 1 The AuNRs-GPLGLAG-CS carrier was obtained by washing twice with % acetic acid solution and once with pure water to convert the system into neutral; finally, it was resuspended with deionized water.

6. Use of the gene drug delivery system according to claim 1 in the preparation of a nanocarrier system for reversing photothermal tolerance and enhancing tumor cell killing.

7. A pharmaceutical preparation containing the gene drug delivery system according to claim 1, wherein the pharmaceutical preparation is in the form of an injection.